Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04854213
Other study ID # 88/20
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 6, 2021
Est. completion date March 2025

Study information

Verified date October 2023
Source National Cancer Institute, Naples
Contact Paolo Muto, MD
Phone 0815903398
Email p.muto@istitutotumori.na.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PRELUDE-1 study is a pilot intervention trial that aims to describe the immunologic and genetic evolutions induced by stereotactic body radiationtherapy (SBRT) treatment in oligometastatic Colorectal Cancer (omCRC) patients with two-three nodules lung-limited disease.


Description:

PRELUDE-1 study is a monocentric pilot interventional trial. The study concerns all patients enrolled with a diagnosis of oligometastatic Colorectal Cancer (omCRC) with two-three nodules lung-limited disease and treated with SBRT technique. SBRT will be delivered according to a risk-adapted protocol. Tumor genetic background will be assessed on primary FFPE (Formalin Fixed Paraffin Embedded) tissues. Liquid biopsy will be done on blood samples collected before radiotherapy (RT) start and after 40 days to monitor tumor DNA evolution. The most direct method to assess cancer genetics relies on sampling of tumor DNA and its characterization through whole genome sequencing techniques (NGS, Next Generation Sequencing). The study will last 48 months, divides as follow: 24 months of enrollment phase and up to 24 months of follow-up. Follow-up will be performed on the 40th day after the end of radiation treatment and then every 3 months until progression.


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date March 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Age <80 years - Cytological or histological diagnosis of colorectal adenocarcinoma - Two or three asymptomatic lung nodules smaller than 25 mm - Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 - Available Formalin Fixed Paraffin Embedded (FFPE) of resected primary tumor - Negative pregnancy test for all potentially childbearing women - Patient candidates to SBRT Exclusion Criteria: - Previous systemic anti-tumor treatments (allowed treatment with capecitabine or fluorouracil and radiotherapy in the neoadjuvant setting of rectal tumors with therapy terminated at least 6 months before) - Neutrophils <2000/mm³ or platelets <100.000/mm³ or hemoglobin <9 g/dl; serum creatinine level> 1.5 times the maximum normal value; GOT and/or GPT >5 times the maximum normal value and/or bilirubin level >3 times the maximum normal value - Previous or concomitant malignant neoplasms (excluding basal or spinocellular cutaneous carcinoma or in situ carcinoma of the uterine cervix) - Active or uncontrolled infections - Other concomitant uncontrolled diseases or conditions contraindicating the study drugs at clinician evaluation - Presence of brain metastases - Refusal or inability to provide informed consent - Impossibility to guarantee follow-up

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Stereotactic Body Radiation Therapy (SBRT)
Radiation treatment

Locations

Country Name City State
Italy Istituto Nazionale Tumori - Fondazione G. Pascale Napoli

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute, Naples

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary To assess the efficacy of SBRT in inducing a regressive genetic trajectory of KRAS gene (evaluated by NGS technique) after SBRT treatment. A genetic regressive trajectory is defined as KRAS mutated (any mutation) before SBRT and wild-type after SBRT (mutKRAS before SBRT?wtKRAS after SBRT). The sample size of the study is planned on this genetic trajectory, assuming a frequency of the phenomenon of 1/130 (as desumed from literature review). To be exhaustive, other realistic combinations are: wtKRAS?wtKRAS; mutKRAS?mutKRAS; wtKRAS?mutKRAS. Other assumptions for sample size calculation are: an alpha value of 0.05; a priori successful events rate of 0.077; 1-beta=0.60. 40 days after the end of RT
Secondary To evaluate the response according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, version 1.1 including any eventual abscopal effect. Up to 24 months after the end of RT
Secondary To evaluate the responses' duration (measured from the time of documented objective response until documented tumor progression). Up to 24 months after the end of RT
Secondary To evaluate the progression-free (PFS) survival (from the data of treatment start untill progression). Up to 24 months after the end of RT
Secondary The toxicity, which will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute, version 5.0, November 27, 2017. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline. Higher scores mean worse outcome. Up to 24 months after the end of RT
Secondary Tumor immune microenvironment in primary tumour Evaluate the tumor immune microenvironment (in particular the number of CD3+/CD8+/Granzyme B+ lymphocytes) of primary CRCs by immunohistochemistry (IHC). 40 days after the end of RT
Secondary Metabolic response (exploratory studies) Assess the value of metabolic response by FDG-PET (fluorodeoxyglucose positron emission tomography) through SUV (Standardized Uptake Value) percentage modifications [(SUV after SBRT-SUV before SBRT/SUV before SBRT)x100]. 40 days after the end of RT
See also
  Status Clinical Trial Phase
Recruiting NCT03941080 - Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer
Completed NCT03213314 - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies N/A
Completed NCT03647839 - Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer Phase 2
Recruiting NCT05057052 - Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis Phase 2
Terminated NCT02316496 - Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study Phase 2
Completed NCT03251612 - Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer Phase 2
Completed NCT02380443 - AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer Phase 2
Recruiting NCT02149784 - Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients Phase 3
Recruiting NCT01959061 - Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases Phase 4
Terminated NCT01668680 - Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma Phase 2
Recruiting NCT05068531 - Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
Not yet recruiting NCT04525807 - Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory
Completed NCT04482608 - The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
Recruiting NCT03193710 - The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved N/A
Suspended NCT04108481 - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT03144804 - A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer Phase 2
Completed NCT03142516 - FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status Phase 2
Active, not recruiting NCT01910610 - Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer Phase 3
Recruiting NCT05759728 - A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer Phase 1/Phase 2
Recruiting NCT04874207 - Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib Phase 4